OncoPharm

Delve into the remarkable journey of trastuzumab, a game-changing cancer therapy stemming from the HER2 gene discovery. Discover how groundbreaking clinical trials and collaborations have paved the way for its use in breast cancer treatment, showcasing inspiring patient success stories. The discussion also highlights the drug's efficacy and safety, including potential risks like cardiomyopathy, ongoing monitoring strategies, and evolving treatment advancements for HER2-positive cases.

Highlighting some of the bright spots, oncopharm & otherwise, for our Holiday episode. Best new drug? Best study? Best movie to take my mind off of a pandemic? Enjoy this episode with a glass of Holiday Cheer.

COVID-19 Vaccines are here!!! Will they work in patients on chemo? What about immunotherapy? Without firm answers to such questions we might as well talk about mRNA vaccines, the breakout star of 2020.

First up we discuss RxPonder and what it adds to adjuvant treatment of breast cancer in the context of TailoRx. Then we discuss a recent study (https://jamanetwork.com/journals/jama/fullarticle/2774295)of additional capecitabine following adjuvant chemo in TNBC and what it adds in the context of CREATE-X.

Discover the latest breakthroughs in colon cancer treatment! The conversation highlights the final OS results of the IDEA trial, comparing 3 vs. 6 months of adjuvant chemotherapy. Also explored are the promising findings from the Keynote 177 trial, showcasing the effectiveness of Pembrolizumab for metastatic colorectal cancer with high microsatellite instability. Tune in for expert insights that could change the landscape of colon cancer care!

The Landmarks in OncoPharm series returns to discuss the practice-changing CLOT trial of a LMWH vs. a vitamin K antatogist for treating cancer-associated VTE. CLOT: https://www.nejm.org/doi/full/10.1056/nejmoa025313

Pembro gets an approval for triple negative breast cancer with quite high PD-L1 expression based on Keynote-355 (https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.1000). Some reassuring information on TKI discontinuation in CML from the LAST study (doi:10.1001/jamaoncol.2020.5774) and an interesting method of identifying predictors of TKI adherence in CML (https://journals.sagepub.com/doi/pdf/10.1177/1078155220970616).

Explore the fascinating journey of ifosfamide, from its German origins to its role as a key oncology drug. Discover how this prodrug is activated and its implications for dosing and toxicity. Learn about its uses in treating lymphoma and sarcoma, along with specific FDA approvals for testicular cancer. Dive into discussions on emetogenicity, myelosuppression, and neurotoxicity risks, while also uncovering essential practices for preventing hemorrhagic cystitis with mesna. A detailed look at high-dose toxicities wraps up this insightful conversation.

The BELLINI trial of venetoxlax in multiple myeloma was put on hold last year due to increased mortality. It's now published (https://doi.org/10.1016/S1470-2045(20)30525-8), so we take a look at the data and the myriad of supportive care concerns.

Discussing three recent publications: 1. Updated results of Keynote-426 (https://doi.org/10.1016/S1470-2045(20)30436-8) 2. Ph+ ALL tx with dasatinib/prednisone --> blinatumomab (https://www.nejm.org/doi/full/10.1056/NEJMoa2016272) 3. Decitabine + G-CSF to prevent AML relapse following alloHSCT (https://ascopubs.org/doi/pdf/10.1200/JCO.19.03277)